Postoperative proton therapy for pancreatic cancer patients enrolled on the Proton Collaborative Group (PCG) registry

Romaine Nichols1, Christopher Morris1, Megan Dunn2, Kiran Prabhu3, Lisa McGee4, William Hartsell4, Oren Cahlon5, Smith Apisarnthanarax6, Carlos Vargas6

1University of Florida, Radiation Oncology, Jacksonville- Florida 32206, USA.
2Proton Cooperative Group, Research, Warrenville- Illinois 60555, USA.
3Procure Proton Therapy Center, Radiation Oncology, Oklahoma City- Oklahoma 73142, USA.
4Northwestern Medicine Chicago Proton Center, Radiation Oncology, Warrenville- Illinois 60555, USA.
5Procure Proton Therapy Center - New Jersey, Radiation Oncology, Somerset- New Jersey 08873, USA.
6Seattle Cancer Care Alliance Proton Therapy Center, Radiation Oncology, Seattle- Washington 98133, USA.
7Mayo Clinic, Radiation Oncology, Phoenix- Arizona 85054, USA.

Background
The PCG registry is a multicenter registry for patients receiving proton therapy for various malignancies. The current abstract reviews the outcomes for patients receiving postoperative proton therapy for resected pancreatic cancer.

Methods
From 2/2013 to 6/2015 12 patients with resected pancreatic adenocarcinoma received postoperative proton therapy. The current study reviews the pretreatment characteristics and outcomes of these patients.

Results
Median age - 72 years (range 52 to 79); Males 8, Females 4; T Stage - T2–3, T3–8, T4–1; N Stage - N1–10, N0–0; Margin Status - Close-5, Positive-3, Negative-4; Surgical approach - open-10, laparoscopic 2; Operations performed - standard pancreaticoduodenectomy-7, pylorus sparing pancreaticoduodenectomy- 4, total pancreatectomy-1; Median lymph nodes taken-19.50 (range 11 to 72); Median lymph nodes positive-2 (range 0 to 7); PNI positive-9, PNI unknown-3; LVI positive-6, LVI negative-3, LVI unknown-3; Median tumor size – 3cm (range 2.2 to 6.2); Median dose delivered – 50.51 Gy(RBE) (range 27.88 to 54.00); Median treatment duration – 38 calendar days (range 25 to 48); One patient died during treatment. Only one patient’s treatment was protracted by more than 5 days. Median available follow up is 0.9 years (range 0.07 to 1.7 years); 1 year survival 54%

Conclusion
Postoperative proton therapy after pancreatectomy was well tolerated without significant toxicity or treatment interruption.